Arbutus Biopharma Corporation ABUS Proceeds from disposition of marketable securities and other investments
Proceeds from disposition of marketable securities and other investments at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's proceeds from disposition of marketable securities and other investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's proceeds from disposition of marketable securities and other investments?
- Arbutus Biopharma Corporation (ABUS) reported proceeds from disposition of marketable securities and other investments of $16M in Q1 2026.
- How has Arbutus Biopharma Corporation's proceeds from disposition of marketable securities and other investments changed year-over-year?
- Arbutus Biopharma Corporation's proceeds from disposition of marketable securities and other investments decreased by 65.3% year-over-year, from $46.07M to $16M.
- What is the long-term trend for Arbutus Biopharma Corporation's proceeds from disposition of marketable securities and other investments?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's proceeds from disposition of marketable securities and other investments has grown at a 21.9% compound annual growth rate (CAGR), from $70.35M to $155.28M.